143 related articles for article (PubMed ID: 27699860)
21. Contact allergy as a therapeutic tool for alopecia areata: application of squaric acid dibutylester.
Happle R; Kalveram KJ; Büchner U; Echternacht-Happle K; Göggelmann W; Summer KH
Dermatologica; 1980; 161(5):289-97. PubMed ID: 7439477
[TBL] [Abstract][Full Text] [Related]
22. Topical immunotherapy with squaric acid dibutylester: unusual hair pigmentary changes in two cases of alopecia areata.
Mastrolonardo M; Diaferio A
J Eur Acad Dermatol Venereol; 2002 Mar; 16(2):186. PubMed ID: 12046838
[No Abstract] [Full Text] [Related]
23. Squaric acid dibutyl ester in the treatment of alopecia areata.
Barth JH; Darley CR; Gibson JR
Dermatologica; 1985; 170(1):40-2. PubMed ID: 3882480
[TBL] [Abstract][Full Text] [Related]
24. Clinical experience on the treatment of alopecia areata with squaric acid dibutyl ester.
Giannetti A; Orecchia G
Dermatologica; 1983; 167(5):280-2. PubMed ID: 6653853
[TBL] [Abstract][Full Text] [Related]
25. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.
Lee S; Kim BJ; Lee YB; Lee WS
JAMA Dermatol; 2018 Oct; 154(10):1145-1151. PubMed ID: 30073292
[TBL] [Abstract][Full Text] [Related]
26. Childhood epidermolysis bullosa acquisita during squaric acid dibutyl ester immunotherapy for alopecia areata.
Guerra L; Pacifico V; Calabresi V; De Luca N; Castiglia D; Angelo C; Zambruno G; Di Zenzo G
Br J Dermatol; 2017 Feb; 176(2):491-494. PubMed ID: 27208509
[TBL] [Abstract][Full Text] [Related]
27. Transient leucoderma appearing in an untreated area following contact immunotherapy for alopecia areata.
Nasca MR; Micali G; Pulvirenti N; Licastro Cicero R
Eur J Dermatol; 1998 Mar; 8(2):125-6. PubMed ID: 9649675
[TBL] [Abstract][Full Text] [Related]
28. Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients.
Sakai K; Fukushima S; Mizuhashi S; Jinnin M; Makino T; Inoue Y; Ihn H
Allergol Int; 2020 Apr; 69(2):274-278. PubMed ID: 31767273
[TBL] [Abstract][Full Text] [Related]
29. Squaric acid dibutylester in alopecia areata: is discomfort really necessary?
Orecchia G; Rabbiosi G
J Am Acad Dermatol; 1987 Apr; 16(4):876. PubMed ID: 3571551
[No Abstract] [Full Text] [Related]
30. Clinical sequelae associated with squaric acid dibutylester topical sensitization.
Foley S; Blattel SA; Martin AG
Am J Contact Dermat; 1996 Jun; 7(2):104-8. PubMed ID: 8796751
[TBL] [Abstract][Full Text] [Related]
31. Topical squaric acid dibutylester therapy for alopecia areata.
Flowers FP; Slazinski L; Fenske NA; Pullara TJ
Cutis; 1982 Dec; 30(6):733-6. PubMed ID: 6756800
[No Abstract] [Full Text] [Related]
32. Treatment of alopecia areata with topical sensitizers.
Sutherland L; Laschinger M; Syed ZU; Gaspari A
Dermatitis; 2015; 26(1):26-31. PubMed ID: 25581667
[TBL] [Abstract][Full Text] [Related]
33. Nickel sensitivity as a complication of squaric acid dibutylester treatment of alopecia areata.
Valsecchi R; Cainelli T
Contact Dermatitis; 1985 Apr; 12(4):234. PubMed ID: 4017578
[No Abstract] [Full Text] [Related]
34. Immunohistological evaluation of alopecia areata treated with squaric acid dibutylester (SADBE).
Johansson E; Ranki A; Reunala T; Kianto U; Niemi KM
Acta Derm Venereol; 1986; 66(6):485-90. PubMed ID: 2433867
[TBL] [Abstract][Full Text] [Related]
35. Squaric acid immunotherapy for warts in children.
Silverberg NB; Lim JK; Paller AS; Mancini AJ
J Am Acad Dermatol; 2000 May; 42(5 Pt 1):803-8. PubMed ID: 10775858
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors for clinical response of alopecia areata to topical immunotherapy with squaric acid dibutylester.
Iijima S; Otsuka F
Arch Dermatol; 1997 Apr; 133(4):539-40. PubMed ID: 9126022
[No Abstract] [Full Text] [Related]
37. Squaric acid dibutylester: indications for use and efficacy in alopecia areata.
Pardasani AG; Turner E; McMichael AJ
Arch Dermatol; 2001 Jul; 137(7):970-2. PubMed ID: 11453831
[No Abstract] [Full Text] [Related]
38. [Pigmentation abnormalities in the course of topical immunotherapy of alopecia areata].
Valsecchi R; Pansera B; Rossi A; Cainelli T
G Ital Dermatol Venereol; 1989; 124(1-2):31-2. PubMed ID: 2527809
[TBL] [Abstract][Full Text] [Related]
39. Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis.
Tosti A; Guidetti MS; Bardazzi F; Misciali C
J Am Acad Dermatol; 1996 Aug; 35(2 Pt 1):199-201. PubMed ID: 8708020
[TBL] [Abstract][Full Text] [Related]
40. Squaric acid dibutyl ester for the treatment of alopecia areata: A retrospective evaluation.
Losol E; Şentürk N
Dermatol Ther; 2021 Jan; 34(1):e14726. PubMed ID: 33377267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
